Related Experiment Video
Updated: Jun 23, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer
1Department of Medicine, Inha University College of Medicine, Incheon 22332, Republic of Korea.
Abstract:
Non-small-cell lung cancer (NSCLC) frequently harbors mutations in the epidermal growth factor receptor (EGFR), with exon 20 insertions comprising 1-10% of these mutations. EGFR exon 20 insertions are less responsive to conventional tyrosine kinase inhibitors (TKIs), leading to the development of targeted agents. This review explores key therapeutic agents, such as Amivantamab, Mobocertinib, Poziotinib, Zipalertinib, and Sunvozertinib, which have shown promise in treating NSCLC with EGFR exon 20 insertions. Amivantamab, a bispecific antibody-targeting EGFR and c-MET, demonstrates significant efficacy, particularly when combined with chemotherapy. Mobocertinib, a TKI, selectively targets EGFR exon 20 mutations but faces limitations in efficacy. Poziotinib, another oral TKI, shows mixed results due to mutation-specific responses. Zipalertinib and Sunvozertinib have emerged as potent TKIs with promising clinical data. Despite these advances, challenges in overcoming resistance mutations and improving central nervous system penetration remain. Future research should focus on optimizing first-line combination therapies and enhancing diagnostic strategies for comprehensive mutation profiling.
Insights
New targeted therapies show promise for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions, a mutation resistant to traditional treatments. Agents like Amivantamab and Mobocertinib offer new hope, though challenges remain.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small-cell lung cancer (NSCLC) frequently exhibits epidermal growth factor receptor (EGFR) mutations.
- EGFR exon 20 insertions represent a subset of these mutations (1-10%) associated with poor response to standard tyrosine kinase inhibitors (TKIs).
Purpose of the Study:
- To review emerging targeted therapeutic agents for NSCLC harboring EGFR exon 20 insertions.
- To evaluate the efficacy and limitations of novel drugs including Amivantamab, Mobocertinib, Poziotinib, Zipalertinib, and Sunvozertinib.
Main Methods:
- Literature review of clinical trials and studies on targeted therapies for EGFR exon 20 insertion NSCLC.
- Analysis of drug mechanisms of action, clinical efficacy data, and resistance patterns.
Main Results:
- Amivantamab, a bispecific antibody, shows efficacy, especially with chemotherapy.
- Mobocertinib, Poziotinib, Zipalertinib, and Sunvozertinib exhibit varying degrees of promise as TKIs, with some facing efficacy limitations or mutation-specific responses.
- Resistance and central nervous system penetration remain key challenges.
Conclusions:
- Targeted agents offer improved treatment options for NSCLC with EGFR exon 20 insertions.
- Further research is needed to optimize combination therapies, overcome resistance, and enhance diagnostic strategies for personalized treatment.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
00:59Gene Therapy